APRE · Aprea Therapeutics, Inc.

Summary

Aprea Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025, with Q4 net loss of $2.5 million ($0.32 per basic share) and full year net loss of $12.6 million ($1.93 per basic share), alongside early clinical proof-of-concept for APR-1051 showing two unconfirmed partial responses in PPP2R1A-mutated endometrial cancer patients. Cash and equivalents stood at $14.6 million as of December 31, 2025, sufficient into Q1 2027 with recent private placement proceeds.

Key takeaways

• Event Type: Results of Operations and Financial Condition; Other Events (Items: 2.02)